Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies

Raymond James  initiated coverage on Rocket Pharmaceuticals Inc  (NASDAQ: RCKT ) with an Outperform  rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs and LAD-I.  Rocket could file for approval in both programs as early as next year, with potential pre-BLA meetings in 2022. Despite the known risks, Raymond James thinks experts favor LVV-based gene therapies in rare pediatric diseases. Related:   Rocket Pharma's ... Full story available on Benzinga.com